

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein do not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein will be offered and sold outside the United States in reliance on Regulation S under the Securities Act (the “**Regulation S**”) and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein is being or will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People’s Republic of China with limited liability)
(Stock Code: 2359)

**FURTHER ADJUSTMENT TO THE CONVERSION PRICE OF US\$300
MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2024**

References are made to the (i) announcements of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” together with its subsidiaries, the “**Group**”) dated September 3, 2019, September 4, 2019, September 5, 2019, September 17, 2019 and June 3, 2020 in relation to, among other things, the issue of US\$300 million zero coupon convertible bonds due 2024 (the “**Bonds**”) and the adjustment to the conversion price of the Bonds from HK\$111.80 per H Share to HK\$79.85 per H Share; and (ii) the circular of the Company dated April 9, 2021 (the “**Circular**”) and the poll results announcement of the Company dated May 13, 2021 (the “**Poll Results Announcement**”) in relation to, among other things, the 2020 Profit Distribution and 2020 Capitalization of Reserve. Unless otherwise stated, the terms used in this announcement shall have the same meanings as defined in the Circular.

As disclosed in the Poll Results Announcement, the Company will distribute cash dividends for the year ended December 31, 2020 and conduct the 2020 Capitalization of Reserve. An aggregate amount of RMB889,579,996.44 (inclusive of tax) (representing a dividend of RMB3.63 (inclusive of tax) per ten (10) Shares based on the total issued Shares as at the date of this announcement) and a total of 490,126,719 Shares comprising 2020 New Capitalization H Shares in the number of 63,155,032 H Shares and 2020 New Capitalization A Shares in the number of 426,971,687 A Shares, based on the Company's total share capital of 2,450,633,599 Shares as at the date of this announcement will be issued on the basis of two (2) 2020 Capitalization Shares for every existing ten (10) Shares by way of capitalization of reserve.

Pursuant to the terms and conditions of the Bonds, the price at which H Shares will be issued upon conversion ("**Conversion Price**") is subject to adjustment for, among other things, capital distributions and capitalization of profits or reserves made by the Company. The Company therefore announces that the Conversion Price of the Bonds will be further adjusted from HK\$79.85 per H Share to HK\$66.17 per H Share (the "**Further Adjusted Conversion Price**") as a result of the approval of the payment of the 2020 Profit Distribution and the 2020 Capitalization of Reserve by the Shareholders at the 2020 AGM with effect from June 8, 2021, being the day immediately after the record date for determining H Shareholders' entitlement to the 2020 Capitalization of Reserve and 2020 Profit Distribution, as well as certain minor rounding adjustments to the Conversion Price of the Bonds over the course of 2020 which were not required to be reflected immediately and have been carried over pursuant to the terms and conditions of the Bonds. Save as disclosed above, all other terms of the Bonds remain unchanged.

As at the date of this announcement, the principal amount of the Bonds which are outstanding is US\$209,900,000. Assuming full conversion of the outstanding Bonds at the Further Adjusted Conversion Price, the H Shares that may be convertible and issuable under the Bonds will increase from approximately 20,619,093 H Shares to approximately 24,881,889 H Shares, representing 7.88% of the total issued H share capital of the Company as at the date of this announcement and approximately 6.16% of the enlarged total issued H share capital of the Company resulting from the full conversion of the outstanding Bonds and the completion of the 2020 Capitalization of Reserve. The additional 4,262,796 H Shares issuable in the event of a full conversion of the outstanding Bonds after the Further Adjusted Conversion Price becoming effective will be allotted and issued by the Company pursuant to the Convertible Bonds-Related Specific Mandate sought and granted at the 2020 AGM held on May 13, 2021.

This announcement also serves as a notification to the holders of the Bonds in respect of the further adjustment to the Conversion Price in accordance with the trust deed constituting the Bonds entered into between the Company and The Hongkong and Shanghai Banking Corporation Limited on September 17, 2019.

Any holder of the Bonds who is in doubt as to the action to be taken should consult his/her/its stockbroker, bank manager, solicitor, professional accountant or other professional adviser.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, June 7, 2021

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purposes only*